2. Search Result
Search Result
Results for "

oral， CB1

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

4

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-119104
    AZD1940

    		Cannabinoid Receptor Neurological Disease
    AZD1940 is an orally active, high affinity cannabinoid CB1/CB2 receptor agonist with pKi values of 7.93 and 9.06 for human CB1R and CB2R, respectively. AZD1940 shows a robust analgesia action .
    AZD1940
  • HY-12095
    CB1 inverse agonist 2

    		Cannabinoid Receptor Neurological Disease
    CB1 inverse agonist 2 is an orally active inverse agonist of Cannabinoid Receptor CB1. CB1 inverse agonist 2 effectively inhibits CP55940-induced hypothermia and anorexia in mice model .
    CB1 inverse agonist 2
  • HY-14791
    Ibipinabant
    1 Publications Verification

    SLV319; BMS-646256

    		 Cannabinoid Receptor Metabolic Disease
    Ibipinabant (SLV319) is a potent, selective and orally active antagonist of cannabinoid CB1 receptor, with a Ki of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (Ki=7943 nM). Ibipinabant can be used for the research of obesity and diabetic .
    Ibipinabant
  • HY-153800
    Monlunabant
    1 Publications Verification

    (S)-MRI-1891; INV-202

    		 Cannabinoid Receptor Arrestin Metabolic Disease
    Monlunabant ((S)-MRI-1891) is an orally active antagonist for cannabinoid receptor 1 (CB1), binds to hCB1 and hCB2 with Ki of 0.3 nM and 613 nM .
    Monlunabant
  • HY-141411A
    Zevaquenabant

    (S)-MRI-1867

    		 Cannabinoid Receptor NO Synthase Metabolic Disease
    Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) .
    Zevaquenabant
  • HY-14900
    Tedalinab

    GRC-10693

    		 Cannabinoid Receptor Inflammation/Immunology
    Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment .
    Tedalinab
  • HY-135280
    MRL-650

    CB1 inverse agonist 1

    		 Cannabinoid Receptor Metabolic Disease
    MRL-650 (CB1 inverse agonist 1) is a highly potent, orally active, and specific inverse agonist of CB1 receptor with IC50s of 7.5 nM and 4100 nM for CB1 and CB2 receptors, respectively. Anorexigenic effects .
    MRL-650
  • HY-148176
    ANEB-001

    		Cannabinoid Receptor Neurological Disease
    ANEB-001 is an orally active CB1 inhibitor, can be used to research acute cannabinoid intoxication .
    ANEB-001
  • HY-106010
    LBP1

    		Cannabinoid Receptor Neurological Disease
    LBP1 is an orally active and low brain penetrant CB1 receptor agonist. LBP1 exhibits significant anti-allodynic and anti-hyperalgesic effects in rodent models of neuropathic pain .
    LBP1
  • HY-12104
    PF-514273

    		Cannabinoid Receptor Metabolic Disease
    PF-514273 is an orally active, selective antagonist for cannabinoid-1 receptor (CB1) with IC50 of 1 nM. PF-514273 reduces the food uptake in mice, and can be used for obesity research .
    PF-514273
  • HY-141411B
    (R)-Zevaquenabant

    (R)-MRI-1867

    		 Drug Isomer Cannabinoid Receptor NO Synthase Others
    (R)-Zevaquenabant ((R)-MRI-1867) is the enantiomer of Zevaquenabant (HY-141411A). Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) .
    (R)-Zevaquenabant
  • HY-P1091
    Hemopressin (human, mouse)

    		Cannabinoid Receptor Neurological Disease
    Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models .
    Hemopressin (human, mouse)
  • HY-124283A
    LEI-101

    		Cannabinoid Receptor Neurological Disease
    LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors .
    LEI-101
  • HY-14788
    Drinabant

    AVE1625

    		 Cannabinoid Receptor Metabolic Disease
    Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R .
    Drinabant
  • HY-P1090
    Hemopressin(rat)

    		Cannabinoid Receptor Neurological Disease
    Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models .
    Hemopressin(rat)
  • HY-P1091A
    Hemopressin(human, mouse) TFA

    		Cannabinoid Receptor Neurological Disease
    Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models .
    Hemopressin(human, mouse) TFA
  • HY-P1090A
    Hemopressin(rat) TFA

    		Cannabinoid Receptor Neurological Disease
    Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models .
    Hemopressin(rat) TFA
  • HY-W005629
    Leelamine

    		Cannabinoid Receptor PDK-1 Metabolic Disease Cancer
    Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC50 value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .
    Leelamine
  • HY-124954
    MN-25

    		Cannabinoid Receptor TNF Receptor Neurological Disease Inflammation/Immunology
    MN-25 (compound 4a) is an orally active indolpyridone that serves as a novel cannabinoid ligand. MN-25 has Ki of 245 nM and 11 nM for CB1 and CB2. MN-25 has CB2 agonist activity and inhibits TNF-R release in human peripheral blood mononuclear cells in vitro with an IC50 of 33 μM. MN-25 shows efficacy in a mouse acute inflammation model at oral doses up to 50 mg/kg >[1].
    MN-25
  • HY-174848
    PQM-244

    		TRP Channel Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    PQM-244 (Compound 5c) is an orally active and multi-target modulator of TRPV1 and CB1 and CB2 receptors. PQM-244 has significant peripheral antinociceptive effects on both neurogenic and inflammatory phases. PQM-244 also has potential antioxidant activity with an IC50  of  14.15 µM for radical scavenging DPPH. PQM-244 can be used for chronic pain and inflammatory disease research, such as diabetes, atherosclerosis and Alzheimer’s disease .
    PQM-244
  • HY-124283
    LEI-101 free base

    		Endogenous Metabolite Inflammation/Immunology
    LEI-101 free base is a selective and orally bioavailable CB2 receptor agonist with the potential to inhibit diseases associated with inflammation and/or oxidative stress. LEI-101 free base has a binding potency to CB2 receptors that is approximately 100 times higher than that to CB1 receptors. Its pEC50 value on CB2 receptors is 8, while its pKi value on hERG is less than 4. LEI-101 may have an inhibitory effect on conditions such as kidney disease .
    LEI-101 free base
  • HY-155967
    CB1R/AMPK modulator 1

    		AMPK Cannabinoid Receptor Metabolic Disease
    CB1R/AMPK modulator 1 (Compound 38-S) is an orally active CB1R/AMPK modulator, with an Ki of 0.81 nM and an IC50 of 3.9 nM for CB1R. CB1R/AMPK modulator 1 activates AMPK. CB1R/AMPK modulator 1 reduces food intake and body weight, and improves glucose tolerance and insulin sensitivity .
    CB1R/AMPK modulator 1
  • HY-107019
    Surinabant

    SR 147778

    		 Cannabinoid Receptor Metabolic Disease
    Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism .
    Surinabant
  • HY-163684
    Zoracopan

    		Complement System Inflammation/Immunology
    Zoracopan is a selective complement factor D (CFD) inhibitor. When administered systemically (orally or intravenously), Zoracopan accumulates and is sustained-released in ocular tissues, primarily in the choroid-retinal pigment epithelium (C-RPE) and/or iridociliary body (I-CB) .
    Zoracopan
  • HY-172808
    BNS808

    		Cannabinoid Receptor Cytochrome P450 Metabolic Disease
    BNS808 is an orally active and selective cannabinoid-1 receptor (CB1R) antagonist (IC50 = 0.8 nM) with notable CB2R selectivity and minimal brain penetration. BNS808 is studied in research on obesity and its associated metabolic complications, such as metabolic dysfunctional-associated steatotic liver disease (MASLD). BNS808 has reduced free drug availability for CNS entry, enhancing safety and minimizing drug-drug interactions through high plasma binding .
    BNS808

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: